The 2025 capital increase of CHF 8 million will secure the product upgrade of TLN-1 (formulation adjustment) and the start of the placebo-controlled LIBRA study with Parkinson's patients.
A market-based assessment confirms the potential of InnoMedica's Parkinson's therapy for a paradigm shift. The world's leading consulting firm, IQVIA, conservatively estimates the sales potential in the US at USD 2.8 to 5.3 billion annually, based on surveys of prescribing physicians and insurers.
The Board of Directors of InnoMedica has decided to carry out a public capital increase with publication in the Swiss Official Gazette of August 18, 2025, and a subscription period until September 30, 2025. While preserving the subscription rights of existing shareholders, at least 2,200,000 and a maximum of 3,200,000 new registered shares are to be placed for CHF 2.50 per share.
You can order the investor documents (Business Information 2025, IQVIA-Report, Subscription Form, Prospectus, Business Report 2024) using this form:
The following information is intended exclusively for persons resident in Switzerland. The public offering of shares of InnoMedica Holding AG is made solely in Switzerland. The information contained on this website does not constitute an offer or solicitation to purchase or subscribe for securities in the United States of America (“USA”), Canada, Japan, Australia, the United Kingdom or in any other jurisdiction in which such an offer or solicitation would be unlawful.
The securities of InnoMedica Holding AG may not be offered or sold in the USA except pursuant to an exemption from the registration requirements under the U.S. Securities Act of 1933, as amended.
By accessing the following pages of this website, you confirm that you are resident in Switzerland and that you have understood and accept these restrictions.
